HDAC9 and cancer: Since HDACs are considered to be attractive targets for cancer prevention and therapy, pan-HDAC inhibitors (HDACis) represent a powerful class of epigenetically active therapeutic drugs that have already demonstrated promising anti-cancer activities in pre-clinical studies and are undergoing clinical trials for many cancers [10, 11].